Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2008

Open Access 01-12-2008 | Research

The inhibition of assembly of HIV-1 virus-like particles by 3-O-(3',3'-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its Zinc-binding domain

Authors: Sandrina DaFonseca, Pascale Coric, Bernard Gay, Saw See Hong, Serge Bouaziz, Pierre Boulanger

Published in: Virology Journal | Issue 1/2008

Login to get access

Abstract

Background

DSB, the 3-O-(3',3'dimethylsuccinyl) derivative of betulinic acid, blocks the last step of protease-mediated processing of HIV-1 Gag precursor (Pr55Gag), which leads to immature, noninfectious virions. When administered to Pr55Gag-expressing insect cells (Sf9), DSB inhibits the assembly and budding of membrane-enveloped virus-like particles (VLP). In order to explore the possibility that viral factors could modulate the susceptibility to DSB of the VLP assembly process, several viral proteins were coexpressed individually with Pr55Gag in DSB-treated cells, and VLP yields assayed in the extracellular medium.

Results

Wild-type Vif (Vifwt) restored the VLP production in DSB-treated cells to levels observed in control, untreated cells. DSB-counteracting effect was also observed with Vif mutants defective in encapsidation into VLP, suggesting that packaging and anti-DSB effect were separate functions in Vif. The anti-DSB effect was abolished for VifC133S and VifS116V, two mutants which lacked the zinc binding domain (ZBD) formed by the four H108C114C133H139 coordinates with a Zn atom. Electron microscopic analysis of cells coexpressing Pr55Gag and Vifwt showed that a large proportion of VLP budded into cytoplasmic vesicles and were released from Sf9 cells by exocytosis. However, in the presence of mutant VifC133S or VifS116V, most of the VLP assembled and budded at the plasma membrane, as in control cells expressing Pr55Gag alone.

Conclusion

The function of HIV-1 Vif protein which negated the DSB inhibition of VLP assembly was independent of its packaging capability, but depended on the integrity of ZBD. In the presence of Vifwt, but not with ZBD mutants VifC133S and VifS116V, VLP were redirected to a vesicular compartment and egressed via the exocytic pathway.
Appendix
Available only for authorised users
Literature
1.
Kanamoto T, Kashiwada Y, Kanbara K, Gotoh K, Yoshimori M, Goto T, Sano K, Nakashima H: Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation. Antimicrob Agents Chemother 2001, 45: 1225-1230.PubMedCentralCrossRefPubMed
2.
Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, Matallana C, Castillo A, Zoumplis D, Martin DE, Orenstein JM, Allaway GP, Freed EO, Wild CT: PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci USA 2003, 100: 13555-13560.PubMedCentralCrossRefPubMed
3.
Li F, Zoumplis D, Matallana C, Kilgore NR, Reddick M, Yunus AS, Adamson CS, Salzwedel K, Martin DE, Allaway GP, Freed EO, Wild CT: Determinants of activity of the HIV-1 maturation inhibitor PA-457. Virology 2006, 356: 217-224.CrossRefPubMed
4.
Zhou J, Chen CH, Aiken C: The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid. Retrovirology 2004, 1: 15.PubMedCentralCrossRefPubMed
5.
Kashiwada Y, Hashimoto F, Cosentino LM, Chen CH, Garrett PE, Lee KH: Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. J Med Chem 1996, 39: 1016-1017.CrossRefPubMed
6.
Zhou J, Yuan X, Dismuke D, Forshey BM, Lundquist C, Lee KH, Aiken C, Chen CH: Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J Virol 2004, 78: 922-929.PubMedCentralCrossRefPubMed
7.
Zhou X, Parent LJ, Wills JW, Resh MD: Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. J Virol 1994, 68: 2556-2569.PubMedCentralPubMed
8.
9.
Pettit S, Moody MD, Wehbie RS, Kaplan AH, Nantermet PV, Klein CA, Swanstrom R: The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J Virol 1994, 68: 8017-8027.PubMedCentralPubMed
10.
Shehu-Xhilaga M, Kräusslich H-G, Pettit S, Swanstrom R, Lee JY, Marshall JA, Crowe SM, Mak J: Proteolytic processing of the p2/nucleocapsid cleavage site is critical for human immunodeficiency virus type 1 RNA dimer maturation. J Virol 2001, 75: 9156-9164.PubMedCentralCrossRefPubMed
11.
Adamson CS, Ablan SD, Boeras I, Goila-Gaur R, Soheilian F, Nagashima K, Li F, Salzwedel K, Sakalian M, Wild CT, Freed EO: In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). J Virol 2006, 80: 10957-10971.PubMedCentralCrossRefPubMed
12.
Sakalian M, McMurtrey CP, Deeg FJ, Maloy CW, Li F, Wild CT, Salzwedel K: 3-O-(3',3'-dimethysuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 Gag precursor assembled in vitro. J Virol 2006, 80: 5716-5722.PubMedCentralCrossRefPubMed
13.
Zhou J, Huang L, Hachey DL, Chen CH, Aiken C: Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles. J Biol Chem 2005, 280: 42149-42155.CrossRefPubMed
14.
DaFonseca S, Blommaert A, Coric P, Hong SS, Bouaziz S, Boulanger P: The 3-O-(3',3'-dimethylsuccinyl) derivative of betulinic acid (DSB) inhibits the assembly of virus-like particles in HIV-1 Gag precursor-expressing cells. Antiviral Ther 2007,12(8):1185-1203.
15.
Kashiwada Y, Sekiya M, Ikeshiro Y, Jujioka T, Kilgore NR, Wild CT, Allaway GP, Lee K-H: 3-O-glutaryl-dihydrobetulin and related monoacyl derivatives as potent anti-HIV agents. Bioorg Med Chem Lett 2004, 14: 5851-5853.CrossRefPubMed
16.
Royer M, Hong SS, Gay B, Cerutti M, Boulanger P: Expression and extracellular release of human immunodeficiency virus type 1 Gag precursors by recombinant baculovirus-infected cells. J Virol 1992, 66: 3230-3235.PubMedCentralPubMed
17.
Yuan X, Huang L, Ho P, Labranche C, Chen CH: Conformation of gp120 determines the sensitivity of HIV-1 DH012 to the entry inhibitor IC9564. Virology 2004, 324: 525-530.CrossRefPubMed
18.
Labrosse B, Pleskoff O, Sol N, Jones C, Henin Y, Alizon M: Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41. J Virol 1997, 71: 8230-8236.PubMedCentralPubMed
19.
Adamson CS, Freed EO: Human immunodeficiency virus type 1 assembly, release and maturation. Adv Pharmacol 2007, 55: 347-387.CrossRefPubMed
20.
Accola MA, Höglund S, Göttlinger HG: A putative alpha-helical structure which overlaps the capsid-p2 boundary in the human immunodeficiency virus type 1 Gag precursor is crucial for viral particle assembly. J Virol 1998, 72: 2072-2078.PubMedCentralPubMed
21.
Bachand F, Yao XJ, Hrimech M, Rougeau N, Cohen EA: Incorporation of Vpr into human immunodeficiency virus type 1 requires a direct interaction with the p6 domain of the p55 gag precursor. J Biol Chem 1999, 274: 9083-9091.CrossRefPubMed
22.
Jenkins Y, Pornillos O, Rich RL, Myszka DG, Sundquist WI, Malim MH: Biochemical analyses of the interactions between human immunodeficiency virus type 1 Vpr and p6(Gag). J Virol 2001, 75: 10537-10542.PubMedCentralCrossRefPubMed
23.
Müller B, Tessmer U, Schubert U, Kräusslich H-G: Human immunodeficiency virus type 1 Vpr protein is incorporated into the virion in significantly smaller amounts than Gag and is phosphorylated in infected cells. J Virol 2000, 74: 9727-9731.PubMedCentralCrossRefPubMed
24.
Bardy M, Gay B, Pébernard S, Chazal N, Courcoul M, Vigne R, Decroly E, Boulanger P: Interaction of human immunodeficiency virus type 1 Vif with Gag and Gag-Pol precursors: co-encapsidation and interference with viral protease-mediated Gag processing. J Gen Virol 2001, 82: 2719-2733.CrossRefPubMed
25.
Akari H, Fujita M, Kao S, Khan MA, Shehu-Xhilaga M, Adachi A, Strebel K: High level expression of human immunodeficiency virus type-1 Vif inhibits viral infectivity by modulating proteolytic processing of the Gag precursor at the p2/nucleocapsid processing site. J Biol Chem 2004, 279: 12355-12362.CrossRefPubMed
26.
Lv W, Liu Z, Jin H, Yu X, Zhang L, Zhang L: Three-dimensional structure of HIV-1 VIF constructed by comparative modeling and the function characterization analyzed by molecular dynamics simulation. Org Biomol Chem 2007, 5: 617-626.CrossRefPubMed
27.
Xiao Z, Ehrlich E, Yu Y, Luo K, Wang T, Tian C, X-F Y: Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology 2006, 349: 290-299.CrossRefPubMed
28.
Xiao Z, Xiong Y, Zhang W, Tan L, Ehrlich E, Guo D, Yu X-F: Characterization of a novel Cullin5 binding domain in HIV-1 Vif. J Mol Biol 2007, 373: 541-550.CrossRefPubMed
29.
Srinivasakumar N, Chazal N, Helga-Maria C, Prasad S, Hammarskjöld M-L, Rekosh D: The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines. J Virol 1997, 71: 5841-5848.PubMedCentralPubMed
30.
Alexander M, Bor Y-C, Ravichandra KS, Hammarskjö_ld M-L, Rekosh D: Human immunodeficiency virus type 1 Nef associates with lipid rafts to downmodulate cell surface CD4 and class I major histocompatibility complex expression and to increase infectivity. J Virol 2004, 78: 1685-1696.PubMedCentralCrossRefPubMed
31.
Cimarelli A, Darlix J-L: Assembling the human immunodeficiency virus type 1. Cell Mol Life Sci 2002, 59: 1166-1184.CrossRefPubMed
32.
33.
34.
Freed EO, Martin MA: Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. J Virol 1996, 70: 341-351.PubMedCentralPubMed
35.
36.
Murakami T, Freed EO: Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail. J Virol 2000, 74: 3548-3554.PubMedCentralCrossRefPubMed
37.
Aiken C, Trono D: Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol 1995, 69: 5048-5056.PubMedCentralPubMed
38.
Forshey BM, Aiken C: Disassembly of human immunodeficiency virus type 1 cores in vitro reveals association of Nef with the subviral ribonucleoprotein complex. J Virol 2003, 77: 4409-4414.PubMedCentralCrossRefPubMed
39.
Welker R, Harris M, Cardel B, Krausslich HG: Virion incorporation of human immunodeficiency virus type 1 Nef is mediated by a bipartite membrane-targeting signal: analysis of its role in enhancement of viral infectivity. J Virol 1998, 72: 8833-8840.PubMedCentralPubMed
40.
Welker R, Kottler H, Kalbitzer HR, Krausslich HG: Human immunodeficiency virus type 1 Nef protein is incorporated into virus particles and specifically cleaved by the viral proteinase. Virology 1996, 219: 228-236.CrossRefPubMed
41.
Mahalingam S, Khan SA, Murali R, Jabbar MA, Monken CE, Collman RG, Srinivasan A: Mutagenesis of the putative alpha-helical domain of the Vpr protein of human immunodeficiency virus type 1: effect on stability and virion incorporation. Proc Natl Acad Sci USA 1995, 92: 3794-3798.PubMedCentralCrossRefPubMed
42.
Morellet N, Bouaziz S, Petitjean P, Roques BP: NMR structure of the HIV-1 regulatory protein Vpr. J Mol Biol 2003, 327: 215-227.CrossRefPubMed
43.
Singh SP, Tomkowicz B, Lai D, Cartas M, Mahalingam S, Kalyanaraman VS, Murali R, Srinivasan A: Functional role of residues corresponding to helical domain II (amino acids 35 to 46) of human immunodeficiency virus type 1 Vpr. J Virol 2000, 74: 10650-10657.PubMedCentralCrossRefPubMed
44.
Yao XJ, Subbramanian RA, Rougeau N, Boisvert F, Bergeron D, Cohen EA: Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation. J Virol 1995, 69: 7032-7044.PubMedCentralPubMed
45.
Accola MA, Bukovsky AA, Jones MS, Göttlinger HG: A conserved dileucine-containing motif in p6(gag) governs the particle association of Vpx and Vpr of simian immunodeficiency viruses SIV(mac) and SIV(agm). J Virol 1999, 73: 9992-9999.PubMedCentralPubMed
46.
Lu YL, Bennett RP, Wills JW, Gorelick R, Ratner L: A leucine triplet repeat sequence (LXX)4 in p6 gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles. J Virol 1995, 69: 6873-6879.PubMedCentralPubMed
47.
Selig L, Pages J-C, Tanchou V, Prévéral S, Berlioz-Torrent C, Liu LX, Erdtmann L, Darlix J-L, Benarous R, Benichou S: Interaction with the p6 domain of the Gag precursor mediates incorporation into virions of Vpr and Vpx proteins from primate lentiviruses. J Virol 1999, 73: 592-600.PubMedCentralPubMed
48.
Votteler J, Studtrucker N, Sörgel S, Münch J, Rücker E, Kirchhoff F, Schick B, Henklein P, Fossen T, Bruns K, Sharma A, Wray V, Schubert U: Proline 35 of human immunodeficiency virus type 1 (HIV-1) Vpr regulates the integrity of the N-terminal helix and the incorporation of Vpr into virus particles and supports the replication of R5-tropic HIV-1 in human lymphoid tissue ex vivo. J Virol 2007, 81: 9572-9576.PubMedCentralCrossRefPubMed
49.
Bouyac M, Courcoul M, Bertoia G, Baudat Y, Gabuzda D, Blanc D, Chazal N, Boulanger P, Vigne R, Spire B: Human immunodeficiency virus type 1 Vif protein binds to the Pr55GAG precursor. J Virol 1997, 71: 9358-9365.PubMedCentralPubMed
50.
Huvent I, Hong SS, Fournier C, Gay B, Tournier J, Carriere C, Courcoul M, Vigne R, Spire B, Boulanger P: Interaction and co-encapsidation of HIV-1 Vif and Gag recombinant proteins. J Gen Virol 1998, 79: 1069-1081.CrossRefPubMed
51.
Baraz L, Friedler A, Blumenzweig I, Nussinuv O, Chen N, Steinitz M, Gilon C, Kotler M: Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production. FEBS Letters 1998, 441: 419-426.CrossRefPubMed
52.
Borman AM, Quillent C, Charneau P, Dauguet C, Clavel F: Human immunodeficiency virus type 1 Vif-mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity. J Virol 1995, 69: 2058-2067.PubMedCentralPubMed
53.
Dettenhofer M, Cen S, Carlson BA, Kleiman L, Yu X-F: Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription. J Virol 2000, 74: 8938-8945.PubMedCentralCrossRefPubMed
54.
Goncalves J, Shi B, Yang X, Gabuzda D: Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains. J Virol 1995, 69: 7196-7204.PubMedCentralPubMed
55.
Kao S, Khan MA, Miyagi E, Plishka R, Buckler-White A, Strebel K: The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol 2003, 77: 11398-11407.PubMedCentralCrossRefPubMed
56.
Karczewski S, Strebel K: Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 vif protein. J Virol 1996, 70: 494-507.PubMedCentralPubMed
57.
Liu H, Wu X, Newman M, Shaw GM, Hahn BH, Kappes JC: The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures. J Virol 1995, 69: 7630-7638.PubMedCentralPubMed
58.
Mehle A, Goncalves J, Santa-Marta M, McPike M, Gabuzda D: Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev 2004, 18: 2861-2866.PubMedCentralCrossRefPubMed
59.
Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D: Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem 2004, 279: 7792-7798.CrossRefPubMed
60.
Mehle A, Wilson H, Zhang C, Brazier AJ, McPike M, Pery E, Gabuzda D: Identification of an APOBEC3G binding site in HIV-1 Vif and inhibitors of Vif-APOBEC3G binding. J Virol 2007, 81: 13235-13241.PubMedCentralCrossRefPubMed
61.
Stephens EB, Singh DK, Pacyniak E, McCormick C: Comparison of Vif sequences from diverse geographical isolates of HIV type 1 and SIV(cpz) identifies substitutions common to subtype C isolates and extensive variation in a proposed nuclear transport inhibition signal. AIDS Res Hum Retroviruses 2001, 17: 169-177.CrossRefPubMed
62.
Ma X-Y, Sova P, Chao W, Volsky DJ: Cysteine residues in the Vif protein of human immunodeficiency virus type 1 are essential for viral infectivity. J Virol 1994, 68: 1714-1720.PubMedCentralPubMed
63.
Simon JHM, Sheehy AM, Carpenter EA, Fouchier RAM, Malim MH: Mutational analysis of the human immunodeficiency virus type 1 Vif protein. J Virol 1999, 73: 2675-2681.PubMedCentralPubMed
64.
Gay B, Tournier J, Chazal N, Carrière C, Boulanger P: Morphopoietic determinants of HIV-1 GAG particles assembled in baculovirus-infected cells. Virology 1998, 247: 160-169.CrossRefPubMed
65.
Royer M, Cerutti M, Gay B, Hong SS, Devauchelle G, Boulanger P: Functional domains of HIV-1 gag -polyprotein expressed in baculovirus-infected cells. Virology 1991, 184: 417-422.CrossRefPubMed
66.
Resh MD: Intracellular trafficking of HIV-1 Gag: how Gag interacts with cell membranes and makes viral particles. AIDS Rev 2005, 7: 84-91.PubMed
67.
Ono A, Freed EO: Cell-type-dependent targeting of human immunodeficiency virus type 1 assembly to the plasma membrane and the multivesicular body. J Virol 2004, 78: 1552-1563.PubMedCentralCrossRefPubMed
68.
Nydegger S, Foti M, Derdowski A, Spearman P, Thali M: HIV-1 egress is gated through late endosomal membranes. Traffic 2003, 4: 902-910.CrossRefPubMed
69.
Sherer NM, Lehmann MJ, Jimenez-Soto LF, Ingmundson A, Horner SM, Cicchetti G, Allen PG, Pypaert M, Cunningham JM, Mothes W: Visualization of retroviral replication in living cells reveals budding into multivesicuar bodies. Traffic 2003, 4: 785-801.CrossRefPubMed
70.
Carrière C, Gay B, Chazal N, Morin N, Boulanger P: Sequence requirement for encapsidation of deletion mutants and chimeras of human immunodeficiency virus type 1 Gag precursor into retrovirus-like particles. J Virol 1995, 69: 2366-2377.PubMedCentralPubMed
71.
Chazal N, Carrière C, Gay B, Boulanger P: Phenotypic characterization of insertion mutants of the human immunodeficiency virus type 1 Gag precursor expressed in recombinant baculovirus-infected cells. J Virol 1994, 68: 111-122.PubMedCentralPubMed
72.
Yao XJ, Rougeau N, Duisit G, Lemay J, Cohen EA: Analysis of HIV-1 Vpr determinants responsible for cell growth arrest in Saccharomyces cerevisiae. Retrovirology 2004, 1: 21.PubMedCentralCrossRefPubMed
73.
74.
Peytavi R, Hong SS, Gay B, Dupuy d'Angeac A, Selig L, Bénichou S, Benarous R, Boulanger P: H-EED, the product of the human homolog of the murine eed gene, binds to the matrix protein of HIV-1. J Biol Chem 1999, 274: 1635-1645.CrossRefPubMed
75.
Douaisi M, Dussart S, Courcoul M, Bessou G, Lerner EC, Decroly E, Vigne R: The tyrosine kinases Fyn and Hck favor the recruitment of tyrosine-phosphorylated APOBEC3G into vif-defective HIV-1 particles. Biochem Biophys Res Commun 2005, 329: 917-924.CrossRefPubMed
76.
Violot S, Hong SS, Rakotobe D, Petit C, Gay B, Moreau K, Billaud G, Priet S, Sire J, Schwartz O, Mouscadet JF, Boulanger P: The Human Polycomb Group EED Protein Interacts with the Integrase of Human Immunodeficiency Virus Type 1. J Virol 2003, 77: 12507-12522.PubMedCentralCrossRefPubMed
Metadata
Title
The inhibition of assembly of HIV-1 virus-like particles by 3-O-(3',3'-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its Zinc-binding domain
Authors
Sandrina DaFonseca
Pascale Coric
Bernard Gay
Saw See Hong
Serge Bouaziz
Pierre Boulanger
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2008
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-5-162

Other articles of this Issue 1/2008

Virology Journal 1/2008 Go to the issue

Research

Effect of influenza and pneumococcal vaccines in elderly persons in years of low influenza activity

Research

La Crosse virus infectivity, pathogenesis, and immunogenicity in mice and monkeys

Research

Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice

Research

Ex vivo promoter analysis of antiviral heat shock cognate 70B gene in Anopheles gambiae

Research

Occult hepatitis B infection: an evolutionary scenario

Short report

A predominance of R5-like HIV genotypes in vaginal secretions is associated with elevated plasma HIV-1 RNA levels and the absence of anti-retroviral therapy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits